What is Gilead Sciences Inc(XSGO:GILD)'s stock price today? The current price of XSGO:GILD is $89.71. The 52 week high of XSGO:GILD is $89.71 and 52 week low is $65.55. When is next earnings date of Gilead Sciences Inc(XSGO:GILD)? The next earnings date of Gilead Sciences...
Get Gilead Sciences Inc. stock quote in real-time, analyze price movement and start CFD trading using our advantages of tight spreads. Buy Gilead Sciences Inc. stock or sell it on IFC Markets.
The company’s Board of Directors declared a quarterly dividend of $0.77 per share of common stock for the first quarter of 2024. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future divid...
The Board declared a quarterly dividend of $0.77 per share of common stock for the third quarter of 2024. The dividend is payable on September 27, 2024, to stock holders of record at the close of business on September 13, 2024. Future dividends will be subject to B...
debt securities, compared to$25.8 billionas ofDecember 31, 2019. During the second quarter 2020, Gilead generated$2.6 billionin operating cash flow, utilized$4.8 billionprimarily related to the acquisition of Forty Seven, paid cash dividends of$856 millionand utilized$54 millionon st...
*Stock Advisor returns as of November 4, 2024 Daniel O'Day--Chairman and Chief Executive Officer Thank you, Jacquie, and good afternoon, everyone. The team and I are pleased to share Gilead's third quarter results, highlighting another very strong quarter of commercial and operational execution...
Stock Comparison Tools FAANG Stocks Gold ETFs Cash Equivalents Big Bank Stocks Big Pharma Stocks Retail Stocks Top Indexes Dow Jones S&P 500 Nasdaq Gold Bitcoin Market Outlook Today's Market US Economy Gold & Precious Metals Commodities Forex Editors' Picks Cryptocurrency Market Data Bond ETFs Commodi...
Primarily represents accelerated stock-based compensation expenses recorded in Cost of goods sold, R&D expenses and Selling, general and administrative (“SG&A”) expenses from the second quarter 2020 Forty Seven acquisition and the fourth quarter 2020 Immunomedics, Inc. (“Immunomedics”)...
I would not be the least bit surprised if they do not repurchase any more shares at the current price level, but this is more of an unknown now under a new CEO. However, the stock is still trading for only about 12 times 2018 free cash flow (assuming a modest uptick in firearms dema...
(I’m not alone in suspecting that it was almost certainly intentional to jack up Gilead’s stock price, a result that was achieved.) Lowe also noted: But now that it’s out there, let’s talk about what’s in the leak. Gilead stock jumped like a spawning salmon in after-market ...